
Neogen Corporation
NEOG · NASDAQ · Healthcare / Medical Devices
Price History
Full chartMarket Stats
About
Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through Food Safety and Animal Safety segments. The company offers diagnostic test kits and complementary products to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns for food producers and processors. It also provides reagents and test kits used in immunoassay production, forensic and animal toxicology, and life science research; unique colorimetric and chemiluminescent substrates for research use; veterinary instruments and delivery systems used for administering antibiotics and vaccines under the Ideal and Prima Tech brands; and precision instruments designed for injections, topical and oral administration, artificial insemination, and animal identification for farmers, ranchers, and veterinarian under the Prima Tech brand. In addition, the company offers digestive aids and nutritional supplements; Natural Vitamin E-AD to address vitamin deficiencies in swine, cattle, and sheep; RenaKare; companion animal parasiticides under Provecta brand; BotVax B; EqStim; ImmunoRegulin, used in dogs to assist in managing pyoderma; companion animal parasiticides under the Provecta brand; rodent and insect control products under the Ramik, CyKill, Havoc, Prozap, SureKill, and StandGuard brands. Further, it markets Uniprim, a veterinary antibiotic; operates sgenomics labs offering DNA genotyping, sequencing, and trait analysis for livestock and companion animals; and provides software systems that help testers to analyze and store results and perform analysis on the results from multiple locations over extended periods. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.
Company Details
- SectorHealthcare
- IndustryMedical Devices
- CEOMr. Mikhael Nassif
- Employees2.64K
- Headquarters620 Lesher Place, Lansing, MI, United States, 48912-1595, USA
- Websitehttps://www.neogen.com
Leadership
- Mr. Mikhael NassifCEO, President & Director · b. 1976
- Mr. R. Bryan Riggsbee CPACFO & Senior Vice President · b. 1970
- Ms. Jennifer Evans Stacey Esq., J.D.Senior VP, Chief Legal & Compliance Officer and Board Secretary · b. 1965
- Dr. Tamara A. Ranalli Ph.D.Senior VP & GM of Global Food Safety · b. 1973
- Mr. John MoylanVP, Corporate Controller & Chief Accounting Officer
- Dr. Jeremy YarwoodChief Scientific Officer
- Sarah DemeyAdministrative Manager
- Mr. Scott GleasonHead of Investor Relations · b. 1979
- Mr. Kevin M. BurkeChief Human Resources Officer · b. 1969
- Mr. Joe FreelsSenior VP & Chief Commercial Officer
Financials
Income Statement
Balance Sheet
Cash Flow
Earnings
Key Statistics & Ratios
Analyst Ratings
- Strong Buy2
- Hold1
Ownership Breakdown
- Institutions
- 110.96%
- Insiders
- 0.74%
- Retail / Other
- 0.00%
Top Institutional Holders
- BlackRock Inc32.62M14.96%
- Vanguard Portfolio Management, LLC12.83M5.88%
- T. Rowe Price Investment Management,Inc.10.16M4.66%
- Dimensional Fund Advisors, Inc.9.83M4.51%
- Vanguard Capital Management, LLC9.57M4.39%
- ING Groep NV8.90M4.08%
- Gates Capital Management Inc8.74M4.01%
- State Street Corp8.59M3.94%
- Mackenzie Investments7.80M3.58%
- Neuberger Berman Group LLC7.75M3.55%
- Hudson Bay Capital Management LP6.50M2.98%
- SG Americas Securities, LLC6.27M2.87%
- CIBC Bancorp USA Inc.5.99M2.75%
- CIBC World Markets Inc.5.96M2.73%
- Geode Capital Management, LLC5.56M2.55%
- BAMCO Inc5.01M2.30%
Top Fund Holders
- iShares Core S&P Small-Cap ETF13.26M6.08%
- Neuberger Genesis Inv7.79M3.57%
- Vanguard MStar Total Stk Mkt Idx Invest6.96M3.19%
- iShares Russell 2000 ETF5.68M2.61%
Stock Splits
- Jun 7, 20212:1
- Jan 2, 20181333:1000
- Oct 31, 20133:2
- Dec 16, 20093:2
- Sep 5, 20073:2
- Jan 2, 20045:4